On Friday, Coherus Oncology Inc (NASDAQ: CHRS) was -6.64% drop from the session before settling in for the closing price of $0.94. A 52-week range for CHRS has been $0.66 – $2.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -27.36% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -646.55%. With a float of $105.41 million, this company’s outstanding shares have now reached $115.91 million.
In an organization with 228 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.52%, operating margin of -58.01%, and the pretax margin is -61.65%.
Coherus Oncology Inc (CHRS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Coherus Oncology Inc stocks. The insider ownership of Coherus Oncology Inc is 9.07%, while institutional ownership is 51.02%. The most recent insider transaction that took place on May 23 ’25, was worth 73,881. In this transaction Director of this company sold 99,988 shares at a rate of $0.74, taking the stock ownership to the 0 shares.
Coherus Oncology Inc (CHRS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -646.55% per share during the next fiscal year.
Coherus Oncology Inc (NASDAQ: CHRS) Trading Performance Indicators
You can see what Coherus Oncology Inc (CHRS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.52. Likewise, its price to free cash flow for the trailing twelve months is 203.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.13, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.82 in one year’s time.
Technical Analysis of Coherus Oncology Inc (CHRS)
Let’s dig in a bit further. During the last 5-days, its volume was 1.76 million. That was better than the volume of 1.71 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 22.61%.
During the past 100 days, Coherus Oncology Inc’s (CHRS) raw stochastic average was set at 37.29%, which indicates a significant increase from 18.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0771 in the past 14 days, which was higher than the 0.0720 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8334, while its 200-day Moving Average is $1.0296. However, in the short run, Coherus Oncology Inc’s stock first resistance to watch stands at $0.9403. Second resistance stands at $1.0028. The third major resistance level sits at $1.0519. If the price goes on to break the first support level at $0.8287, it is likely to go to the next support level at $0.7796. The third support level lies at $0.7171 if the price breaches the second support level.
Coherus Oncology Inc (NASDAQ: CHRS) Key Stats
There are 115,933K outstanding shares of the company, which has a market capitalization of 101.77 million. As of now, sales total 266,960 K while income totals 28,510 K. Its latest quarter income was 7,600 K while its last quarter net income were -56,570 K.
